1. Experimental Hematology
Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators 
Stéphane Lepretre, Carlos Graux, Aurore Touzart, Elizabeth Macintyre, Nicolas Boissel 
Experimental Hematology 
Volume 51, Pages 7-16 (July 2017)
DOI: /j.exphem
Copyright © 2017 ISEH - International Society for Experimental Hematology Terms and Conditions

2. Figure 1
Treatment protocol in the GRAALL-LYSA LL03 study. The GRAALL-LYSA LL03 protocol consisted of a corticosteroid prephase, a five-drug induction with sequential administration of cyclophosphamide (hyperC sequence), dose-dense consolidation, late intensification, CNS prophylaxis with intrathecal chemotherapy and cranial irradiation, and a 2-year maintenance phase [36]. Allogeneic SCT was offered in first CR or unconfirmed CR to patients with high-risk disease who had a suitable donor. Ara-C = cytarabine; CPM = cyclophosphamide; DNR = daunorubicin; DXM = dexamethasone; G-CSF = granulocyte colony-stimulating factor (lenograstim); IDA = idarubicin; i.t. = intrathecal; L-asp = L-asparaginase; MPDN = methylprednisolone; MTX = methotrexate; PDN = prednisone; VCR = vincristine; VP-16 = etoposide; 6-MP = 6-mercaptopurine.
Experimental Hematology  , 7-16DOI: ( /j.exphem )
Copyright © 2017 ISEH - International Society for Experimental Hematology Terms and Conditions